Summary of findings for the main comparison. Anti‐histamines for prolonged non‐specific cough in children.
| anti‐histamines for prolonged non‐specific cough in children | ||||||
| Patient or population: patients with prolonged non‐specific cough in children Settings: Cough reported as an adverse events in safety studies Intervention: anti‐histamines | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | anti‐histamines | |||||
| Number of participants with increased cough | Study population | OR 1.47 (0.86 to 2.49) | 3090 (4 studies) | ⊕⊕⊕⊝ moderate1,2 | ||
| 17 per 1000 | 25 per 1000 (15 to 41) | |||||
| Medium risk population | ||||||
| 20 per 1000 | 29 per 1000 (17 to 48) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Direction of one study favoured anti‐histamines while rest favoured placebo 2 Studies were not designed for efficacy in management of cough in children with allergic rhinitis but cough was recorded as an adverse event